Leerink Partnrs Forecasts Editas Medicine Q3 Earnings

Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Research analysts at Leerink Partnrs issued their Q3 2025 earnings per share (EPS) estimates for shares of Editas Medicine in a research report issued on Wednesday, April 16th. Leerink Partnrs analyst M. Foroohar forecasts that the company will earn ($0.14) per share for the quarter. The consensus estimate for Editas Medicine's current full-year earnings is ($2.71) per share. Leerink Partnrs also issued estimates for Editas Medicine's Q4 2025 earnings at ($0.14) EPS.

Editas Medicine Stock Up 3.5 %

Shares of NASDAQ:EDIT traded up $0.06 during trading on Friday, hitting $1.62. 1,293,372 shares of the company traded hands, compared to its average volume of 2,582,231. Editas Medicine has a one year low of $0.91 and a one year high of $6.69. The business's fifty day moving average is $1.47 and its 200-day moving average is $1.86. The stock has a market capitalization of $135.19 million, a price-to-earnings ratio of -0.63 and a beta of 2.16.

Editas Medicine (NASDAQ:EDIT - Get Free Report) last announced its quarterly earnings data on Wednesday, March 5th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.16). Editas Medicine had a negative net margin of 340.96% and a negative return on equity of 80.13%. The firm had revenue of $30.60 million during the quarter, compared to the consensus estimate of $37.17 million. During the same period in the prior year, the firm earned ($0.23) earnings per share.

Hedge Funds Weigh In On Editas Medicine

Several large investors have recently bought and sold shares of the stock. Raymond James Financial Inc. acquired a new stake in shares of Editas Medicine in the fourth quarter valued at $303,000. Barclays PLC boosted its holdings in Editas Medicine by 46.9% during the third quarter. Barclays PLC now owns 178,507 shares of the company's stock worth $607,000 after buying an additional 56,986 shares in the last quarter. Monaco Asset Management SAM acquired a new position in Editas Medicine in the fourth quarter worth approximately $1,359,000. Stifel Financial Corp increased its holdings in shares of Editas Medicine by 37.9% in the third quarter. Stifel Financial Corp now owns 624,876 shares of the company's stock valued at $2,131,000 after buying an additional 171,656 shares in the last quarter. Finally, SG Americas Securities LLC lifted its position in shares of Editas Medicine by 103.7% during the 4th quarter. SG Americas Securities LLC now owns 81,669 shares of the company's stock valued at $104,000 after acquiring an additional 41,573 shares during the last quarter. Institutional investors and hedge funds own 71.90% of the company's stock.

About Editas Medicine

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.